This publication describes a method for the determination of total bisphenol A (BPA and conjugated BPA) following enzyme hydrolysis and is intended as a companion to our previously developed analytical method for the determination of free BPA (the aglycone) in human blood and urine using high-performance liquid chromatographytandem mass spectrometry (1). That free BPA method provided a means to account for and/or eliminate background contamination and demonstrated accuracy and reproducibility in both matrices fortified with BPA or a surrogate analyte ( 13 C BPA) at a low method quantitation limit (MQL) of 0.1-0.2 ng/mL. In contrast to the free BPA method results and based on stringent accuracy, precision and confirmation criteria set for the MQLs of the method developed for total BPA, the MQL achieved in blood was 1.020 -2.550 and 0.510 -1.020 ng/mL in urine. These data showed higher MQLs than the desired MQLs of 0.5 ng/mL (blood) and 0.2 ng/mL (urine) with increased variability between analyses which demonstrates the importance of generating method validation data with each analysis. In contrast, the MQL achieved for 13 C BPA-G (monoglucuronide as a surrogate analyte in blood was 0.2 -0.5 and 0.2 ng/mL in urine illustrating that the method is capable of meeting lower MQL requirements if the contribution from exogenous BPA can be well controlled. This method for the determination total BPA in human blood and urine is intended to be used in conjunction with the free BPA method (1) to obtain accurate and complete BPA biomonitoring data to support human exposure assessments.
This publication describes a method for the determination of total bisphenol A (BPA and conjugated BPA) following enzyme hydrolysis and is intended as a companion to our previously developed analytical method for the determination of free BPA (the aglycone) in human blood and urine using high-performance liquid chromatographytandem mass spectrometry (1) . That free BPA method provided a means to account for and/or eliminate background contamination and demonstrated accuracy and reproducibility in both matrices fortified with BPA or a surrogate analyte ( 13 C BPA) at a low method quantitation limit (MQL) of 0.1-0.2 ng/mL. In contrast to the free BPA method results and based on stringent accuracy, precision and confirmation criteria set for the MQLs of the method developed for total BPA, the MQL achieved in blood was 1.020 -2.550 and 0.510 -1.020 ng/mL in urine. These data showed higher MQLs than the desired MQLs of 0.5 ng/mL (blood) and 0.2 ng/mL (urine) with increased variability between analyses which demonstrates the importance of generating method validation data with each analysis. In contrast, the MQL achieved for 13 C BPA-G (monoglucuronide as a surrogate analyte in blood was 0.2 -0.5 and 0.2 ng/mL in urine illustrating that the method is capable of meeting lower MQL requirements if the contribution from exogenous BPA can be well controlled. This method for the determination total BPA in human blood and urine is intended to be used in conjunction with the free BPA method (1) to obtain accurate and complete BPA biomonitoring data to support human exposure assessments.
Introduction
Accurate analysis of bisphenol A (BPA) at sub-ppb levels is a very stringent task as BPA is a widely used material and is ubiquitous in the environment at trace concentrations (e.g., surface water and dust). Sub-ppb levels of BPA are also where the current low levels of BPA, primarily its glucuronidated conjugate (BPA-G), has been detected in blood and urine as a result of low-level dietary intake (2, 3). BPA's ubiquitous low-level environmental presence often leads to contamination of human specimens either during or after specimen collection and can contribute to concentration of free BPA (unconjugated BPA) as has been reported in the previous urine and blood biomonitoring studies (4, 5) . This is also evident from the fact that, BPA has been reported for other environmental samples (6) even when products are presumed to be 'BPA-free' (7, 8) . Apart from the exogenous BPA contributing to the reporting of systemic BPA, it has also been reported that the hydrolysis of conjugated forms of BPA can occur during sample collection, handling and analysis and could contribute to the reported values (9, 10) . This point assumes importance as it is understood that the orally administrated BPA dose gets metabolized via presystemic clearance majorly as BPA-G and to a lesser extent as sulfate conjugate of BPA (BPA-S) (11 -13) . Therefore, reporting of only free BPA in human specimens, in the absence of demonstrated BPA conjugate stability, raises questions as to the validity of some of the reported studies. Also, many published papers on biomonitoring studies do not describe the sample preparation and analytical methods in detail which makes it difficult to ascertain if the methods used were fully validated and if there was appropriate use of a solvent standards, blanks, matrix controls and fortified matrix controls to assure data quality. In addition, often it is not documented if the specimen collection and storage devices were screened to confirm the absence of BPA. Hence, there is a need for careful quality control in the sample preparation and analysis to avoid and minimize possible artifacts or contamination (4, 14) . Limited numbers of human and animal studies have employed 13 C BPA and 13 C BPAG as surrogate analytes to circumvent this limitation. These stable-isotope surrogates of BPA and BPA-G were employed in this study to generate method evaluation data without the contribution of background 12 C BPA. Given the abovementioned complexities and importance of generating accurate and precise trace-level BPA biomonitoring data, the current paper describes total BPA analysis methodology which was designed to provide validated data (method performance) with high selectivity and sensitivity, for each sample set processed and analyzed. This method had a method quantitation limits (MQL) targeted at 0.2 and 0.5 ng/mL for the accurate determination of the total BPA (free þ conjugate) in human blood and urine, respectively. To generate method validation data without the issue of background BPA contribution, this study employed 13 C BPA and 13 C BPAG as surrogate analytes. The target MQLs were selected with the goal of having the final total BPA method validated at relevant (real-world) BPA levels expected in biomonitoring samples, given the known pharmacokinetics of BPA and background levels of exogenous BPA from multiple sources likely to be encountered. The buffer solution used during enzyme hydrolysis was prepared by dissolving 18.4 g of citric acid monohydrate and 6.5 g of sodium hydroxide into 1000 mL of Omnisolve water ( pH 4.5 -5.0). All water (Omnisolve) and solvents used in the study were of HPLC grade or higher and continuously screened via reagent blanks.
Materials and methods
The human urine and whole blood samples were obtained under controlled collection, packaging and shipping conditions from Bioreclamation Inc. Hicksville, NY, USA as outlined below. Urine was collected as a single-void into glass containers. Additional glass containers were filled with 400 mL of clean water (Omnisolve HPLC grade) at the time of urine collection to serve as collection device blanks (controls). The urine samples and device controls were frozen at 2208C and shipped on dry ice.
Whole blood (6.0 mL) was obtained via direct venipuncture using a double-sided needle with collection directly into Becton Dickinson (BD) polypropylene vacutainers, K2 EDTA (10.8 mg), BD-REF 367863, Franklin Lakes, NJ, USA. The rationale for the direct venipuncture blood collection is presented in the Discussion. Additional blood-collection vacutainers were filled with 5 mL of clean water (Omnisolve HPLC grade) using the same collection techniques employed for sample collection to serve as device blanks (controls). An additional precaution was implemented with this study to eliminate the potential variability between lots of blood-collection tubes and double-sided needles, and to ensure proper storage conditions. Blood-collection kits were prepared and stored under controlled conditions. Each kit contained five tubes and a double-sided needle sealed in packaging. The tubes were of all the same lot number with 10% screened for 12 C BPA contamination. This practice ensured that blood collection would be conducted with the highest confidence that no BPA contamination would result from the collection devices. The blood samples and device controls were shipped on wet ice.
Following collection, the urine and blood specimens were shipped overnight to MPI Research, State College, PA, USA. The Bioanalytical Laboratory at MPI Research screened the collection device blanks and individual urine and blood specimens to determine the level of free and/or total 12 C BPA before pooling.
Based on the screening results, individual urine samples were deemed suitable for pooling if the free BPA levels were 0.0323 -0.372 ng/mL and the total BPA levels were 0.704 -5.54 ng/mL and total BPA levels in blood were 0.0989 -0.302 ng/mL. The suitability of the individual specimens to be included in the pooled matrix was based on two factors: (i) the expected endogenous BPA level in the pooled matrix be no higher than one half of the lowest fortification level for the validation samples and (ii) having enough pooled matrix for the planned replicates at all of the fortification levels. The urine and blood specimens deemed suitable for use in this validation study were pooled (equal volume), fortified and then transferred to the QC department of MPI Research for randomization. All human volunteers donating control biological samples gave informed consent for their donations and all personal identifying information was removed from the control urine and blood samples prior to receipt at the analytical testing laboratories.
Sample fortification and randomization
In contrast to our previously published free BPA study which used four matrices (water, acetonitrile, human urine and blood), only the two matrices of interest (human urine and blood) were used for this study. The water and acetonitrile were used in the free BPA study to generate data in clean solvents which aided in the data interpretation and method validation for that study and were deemed to have limited value for this study as the prior work demonstrated that there was excellent reproducibility and reliability in LC -MS methods used for determination of BPA in these matrices. The preparation of the desired number of replicates for each matrix at each fortification level was accomplished with the creation of a larger 'master sample' which consisted of pooled matrix ( prepared from previously screened individual sample matrix) fortified at the desired level and sub-aliquots of this master sample dispensed to individual vials. This design provided enough replicates to ensure five replicates of each type of control, fortified control and validation sample per sample set and a minimum of two sample sets.
The various controls, fortified controls and validation samples were used to evaluate contamination, background levels of BPA and/or BPAG, determine BPAG stability and/or BPAG . BPA enzymatic hydrolysis efficiency and determine method performance.
Controls consist matrix with no fortification of analyte, surrogate analyte or IS and served to verify the matrix was free of any contamination or interference for each compound.
The analyte only samples consist matrix fortified with 12 C BPAG and served to verify the 12 C BPAG had no isotopic contribution to the surrogate analyte or IS. The 13 C BPAG authentic standard was not available at the time of the urine sample fortification; therefore, the surrogate analyte only urine samples contained just 13 C BPA and served to verify the 13 C BPA had no contribution to the analyte or IS.
The surrogate analyte only blood samples contained just 13 C BPAG and served to verify the 13 C BPAG had no isotopic contribution to the analyte or IS.
The IS only samples consist matrix fortified with D 8 -BPA and served to verify the D 8 -BPA had no isotopic contribution to the Elucidation of Factors Influencing BPA Method Accuracy and Sensitivity 195 analyte or surrogate. In addition, these samples were used to determine the background level of BPA in pooled matrix and this level was subtracted from the BPA level observed in the respective validation sample.
The urine validation samples consist 11 replicates per concentration fortified with analyte ( and 20.4 ng/mL following enzyme hydrolysis. The urine samples that received no analyte fortification were used to confirm the level of total BPA in the pooled matrix before fortification and allowed for accurate subtraction of this level from the total BPA level observed in the fortified samples.
The blood validation samples consist 20 replicates per concentration fortified with analyte ( 12 C BPAG) and surrogate analyte ( 13 C BPAG) at 0 and 0.40, 1.0, 2.0, 5.0 and 10.0 ng/mL. These concentrations were selected to yield analyte ( 12 C BPA) and surrogate ( 13 C BPA) concentrations at 0 and 0.20, 0.5, 1.0, 2.5 and 5.0 ng/mL following enzyme hydrolysis. The blood samples that received no analyte fortification were used to confirm the level of total BPA in the pooled matrix before fortification and allowed for accurate subtraction of this level from the total BPA level observed in the fortified samples.
In addition to the controls and samples prepared above, laboratory reagent blanks (LRBs) were prepared and analyzed along with each set of samples. The reagent blank consisted of reagent grade water (of equal volume to the respective sample matrix) taken through the entire sample preparation and analysis process to monitor for BPA contamination from laboratory reagents, apparatus, techniques or instrumentation.
Following fortification all validation samples were randomized by the QC department of MPI Research. The analysis laboratory was provided the following information; the type and total volume of each matrix contained in each sample, the concentration range of the analyte and surrogate, the recommended IS fortification level, and which samples should receive no IS.
Sample storage
The urine samples were frozen at 2208C until preparation and analysis. The blood samples were stored on wet ice or at 48C until same-day shipment rather than at 2208C to prevent lysis of red blood cells which complicates whole blood sample preparation. Each analysis batch consists two replicates per matrix of 'analyte only', 'surrogate only' and 'IS only' samples. Each analysis batch also consists five replicates per matrix of each fortification level for the samples containing both analyte and surrogate analyte. Each analysis batch also contained five replicates per matrix of true blank samples. All remaining validation samples were stored at 2208C (48C for blood) for reanalysis if needed.
Sample preparation A 5 mL aliquot of each human urine sample was transferred into a 15-mL glass tube. A 10 mL aliquot of a 1000 ng/mL D 8 -BPA IS solution was added to each sample. All of the samples were diluted with 5 mL of buffer solution ( pH 4.5 -5.0). Fifty microliters of b-glucuronidase (Type HP-2) was added to each sample to convert BPAG to BPA. The samples were then incubated in an oscillating water bath at 37 + 28C for 16 h (overnight). The samples were loaded onto a conditioned glass HLB 5 cc/200 mg solid phase extraction (SPE) column without vacuum. After the total sample had been passed through the column, the sample vial was rinsed with 5 mL of water and the rinsate was added to the column. The column was washed with 3 mL of 50% methanol in water, followed by 5 mL of water, followed by 3 mL of methanol:ammonium hydroxide:water (100:20:880, v/v/v). The columns were dried with medium vacuum for 5 s. Five milliliters of water were added to the column and the column was again dried with medium vacuum for 5 s. Three milliliters of 50% methanol in water were added to the column and the column was dried with medium vacuum for 5 s. Finally, 3 mL of dichloromethane (DCM) was added to the column and the column was dried for 1 min with high vacuum. The BPA analyte was eluted from the SPE column with 4 mL of methyl tert butyl ether (MTBE) directly into a 10-mL glass tube without vacuum (not using the SPE block). The sample eluate, in the 10 mL glass tube, was blown to dryness using a gentle nitrogen flow while placed in a water bath set at 608C. The sample was reconstituted with 1.0 mL of acetonitrile/water (50/50, v/v). The sample was then vortex mixed for 30 s and a portion was transferred to an autosampler vial for analysis using high-performance liquid chromatography with negative ion electrospray ionization and tandem mass spectrometry (HPLC-NESI-MS-MS).
A 2 mL aliquot of each human blood sample was transferred into a 15-mL glass tube. A 6 mL aliquot of a 1000 ng/mL D 8 -BPA solution was added to each sample. All of the samples were diluted with 5 mL of buffer solution ( pH 4.5 -5.0). Fifty microliters of b-glucuronidase (Type HP-2) were added to each sample. The samples were then incubated in an oscillating water bath at 37 + 28C for 16 h (overnight). The samples were loaded onto a conditioned glass HLB 5 cc/200 mg SPE column without vacuum. Five milliliters of water were added to the column and the column was dried with medium vacuum for 5 s. Three milliliters of 50% methanol in water was added to the column and the column was dried with medium vacuum for 5 s. Finally, 3 mL of DCM was added to the column and the column was dried for 1 min with high vacuum. The analyte was eluted from the SPE column with 4 mL of MTBE directly into a 10-mL glass tube without vacuum (not using the SPE block). The sample eluate, in the 10 mL glass tube, was blown to dryness using a gentle nitrogen flow while placed in a water bath set at 608C. The sample was reconstituted with 0.6 mL of acetonitrile/ water (50/50, v/v). The sample was then vortex mixed for 30 s and a portion was transferred to an autosampler vial for analysis using HPLC-NESI -MS-MS.
Each set of matrix samples prepared included the appropriate 'laboratory' blanks (i.e., the solvent blanks from each laboratory), controls and fortified controls to ensure accuracy and precision. All samples were prepared for analysis within 10 days of fortification and all analysis completed within 2 days of preparation.
Standard calibration
The levels of 12 C-and 13 C BPA were quantified using IS calibration. Each set of samples was analyzed with mixed calibration standards consisting equal levels of 12 C-and 13 C BPA fortified in 50:50 acetonitrile:water at 0, 0.100, 0.200, 0.500, 1.000, 5.00, 10.00, 20.00 and 25.0 ng/mL. Each calibration standard was fortified with D 8 -BPA IS at 5 ng/mL. The calibration standards were analyzed before and after each set of validation samples with all results used to construct the calibration curve.
Sample analysis
All analyses were conducted using HPLC -NESI -MS-MS. The HPLC system consisted of an Agilent Technologies (Santa Clara, CA, USA) binary pump, a thermostatically controlled column compartment and a thermostatically controlled well-plate auto sampler. The HPLC systems were interfaced to AB Sciex API 5000 Tandem Mass Spectrometers. Analysis was performed using multiple reaction monitoring (MRM). Mass spectrometry data were collected, processed and stored using the Analyst 1.4.x software.
Typical LC-NESI-MS-MS parameters
HPLC Column: Luna Phenyl-Hexyl column, 3 mm, 150 Â 3.0 mm (Phenomenex P/N: 00F-4256-Y0). 
Results

HPLC-MS-MS analytical method
The analytical method showed acceptable chromatographic separation and the MS -MS operating conditions provided for the needed sensitivity and selectivity for BPA analysis in urine and blood extracts. Typical HPLC -MS-MS extracted MRM ion chromatograms for pooled urine and blood samples and fortified pooled urine and blood samples are presented in Figures 1, 2, 3 and 4. The stated concentrations in each figure are equivalent to the actual concentration of BPA in the initial urine or blood sample before preparation. Sample preparation resulted in theoretical concentration factor of 2Â for urine samples and 3.3Â for blood samples. However, the ion chromatograms demonstrate the differing effects that can be observed from the urine and blood matrices and the importance of stable-isotope IS calibration.
Calibration
For HPLC -MS-MS analysis of 12 C-and 13 C BPA, an eight-point calibration curve was analyzed at the beginning and end of the analytical sequence for the compounds of interest. The calibration standards were prepared in 50/50 acetonitrile/water at 0.10, 0.20, 0.50, 1.00, 5.00, 10.0, 20.0 and 25.0 ng/mL. Each standard contained the IS, D 8 BPA, at a concentration of 5.0 ng/mL. A calibration curve was calculated using the analyte peak/IS peak area versus analyte concentration/IS concentration ratio. Using linear fit regression with (1/x) weighting, the slope, y-intercept and correlation coefficient (r) were determined. A calibration curve was acceptable if r ! 0.990 (r 2 ! 0.980). The total BPA response for all blood samples was ,10 ng/mL calibration standard response, therefore the 20 and 25 ng/mL calibration standards, although analyzed, were not required and were excluded from the calibration curves used for the blood sample sets.
Analyte confirmation
The additional criterion of MS -MS transition ratio was added to these data to improve the method specificity. This ratio is defined as the average of the confirmation ion transition response divided by the quantitation ion transition response observed for the solvent standards analyzed in a given sample set. The acceptance criteria for the sample transition ratio were +20% of the average standard transition ratio.
Blanks
Instrument double blanks in the form of acetonitrile were analyzed. Also, three LRBs in the form of reagent water (of equal volume to the respective sample matrix) fortified with IS and subjected to the same enzyme hydrolysis and analysis procedures used for the samples were included in each sample set. The average LRB observed for urine analysis sets was 0.064 + 0.021 ng/mL (n ¼ 3) and 0.041 + 0.008 ng/mL (n ¼ 3) for analysis sets one and two, respectively. The average LRB observed for blood analysis sets was 0.440 + 0.330 ng/mL (n ¼ 3) and 0.237 + 0.021 ng/mL (n ¼ 3) for analysis sets one and two, respectively. The LRBs were used for monitoring the laboratory sample preparation procedure for BPA contamination.
As stated in the Materials and Methods, urine and blood samples were screened and then pooled if the background level of total BPA was low enough to support the targeted fortification levels. In addition, five replicates of the appropriate pooled matrix (no analyte fortification) were analyzed with each set of validation samples to determine an accurate total BPA background level to be subtracted from the total BPA levels observed in the validation samples. The average total BPA observed in pooled urine was 0.917 + 0.050 ng/mL (n ¼ 5) and 0.879 + 0.042 ng/mL (n ¼ 5) for analysis sets one and two, respectively. The average total BPA observed in pooled blood was 0.137 + 0.035 ng/mL (n ¼ 5) and 0.314 + 0.126 ng/mL (n ¼ 5) for analysis sets one and two, respectively. These levels are also presented as footnotes in Tables I and II. Concentrations of BPA in all urine and blood sample collection device blanks were below the detection limit of 0.05 ng/mL in solvent. The detection limit was set at lowest calibration standard analyzed (0.05 ng/mL) which provided reproducible response to meet the MS -MS transition ratio criteria.
Enzyme hydrolysis efficiency
In addition to other factors that can effect enzyme hydrolysis efficiency (see Discussion), the amount of organic solvent introduced into the system should be limited. During this study, it has been observed that the presence of acetonitrile .0.5% in the sample limits the efficacy of the enzyme activity as shown in Table III . Additional experiments showed a further loss of enzyme efficiency (down to 20-40%) at lower nominal BPA (BPA from BPA-G) concentrations (,2 ng/mL) when acetonitrile (ACN) levels exceeded 1% as shown in Table IV .
The human urine and blood samples for this study utilized fortification volumes between 0.01 and 0.06% ACN per sample matrix volume. For each urine sample, 10 mL of IS in 50% ACN was added to a 5 mL urine aliquot (0.1% ACN). For each blood sample, 6 mL of IS in 50% ACN was added to a 2 mL blood aliquot (0.15% ACN).
Method note: When necessary, a mixed fortification stock solution (containing more than one analyte or surrogate) may be required, so as to not exceed the 0.5% acetonitrile threshold.
Isotopic crossover contribution
The results from the 'analyte only', 'surrogate analyte only' and 'IS only' samples showed no evidence of isotopic crossover contribution between the analytes and IS.
Validation results
The validation results for total 12 C BPA in human urine fortified with known amounts of 12 C BPAG are presented in Table I . The average background concentrations were 0.917 + 0.050 ng/mL (set #1) and 0.879 + 0.042 ng/mL (set #2) 12 C BPA in the pooled human urine matrix used for these validation samples. This background 12 C BPA level was subtracted from the 12 C BPA levels observed at all urine fortification levels.
The urine results show a general trend of the accuracy of the 12 C BPA analyses improving as the fortification concentration of 12 C BPA increased with accuracies of 120% (set #1) and 137% (set #2) at the 0.510 ng/mL fortification level and 84% (set #1) and 104% (set #2) at the 20.400 ng/mL fortification level. The precision results were consistent across all fortification levels with the relative standard deviation (RSD) between 2 and 9%.
The urine validation results for 13 C BPA surrogate show improved accuracy and precision when compared with the 12 C BPA results. The 13 C BPA accuracy ranged from of 94 to 112% and the precision (RSD) ranged from 1 to 11% across all fortification levels.
The validation results for total 12 C BPA in human blood fortified with known amounts of 12 C BPAG are presented in (1) All 12 C-and 13 C BPA data based on n ¼ 5 unless otherwise stated, n , 5 due to isotope transition ratio outside of criteria. (2) The average background 12 C BPA (0.137 ng/mL) observed in the pooled set #1 blood was subtracted from the 12 C BPA observed in the fortified samples. (3) The average background 12 C BPA (0.314 ng/mL) observed in the pooled set #2 blood was subtracted from the 12 C BPA observed in the fortified samples. Table II . An average background concentration of 0.137 + 0.035 ng/mL (set #1) and 0.314 + 0.126 ng/mL (set #2) 12 C BPA in the pooled human blood matrix used for these validation samples. This background 12 C BPA level was subtracted from the 12 C BPA levels observed at all blood fortification levels.
The set #1 blood results show a general trend of the accuracy of the 12 C BPA analyses improving as the fortification concentration of 12 C BPA increased. An accuracy of 293% was observed at the 0.204 ng/mL fortification level and 79% at the 5.100 ng/mL fortification level. The set #2 blood results show improved accuracy over set #1; and again, the 12 C BPA analyses improving as the fortification concentration of 12 C BPA increased, with accuracy ranging from 75% at the 0.510 ng/mL fortification level to 137% at the 1.020 ng/mL fortification level. The precision results for blood showed more variation when compared with the urine data. The precision results showed high RSD values of 66 and 114% at the 0.204 ng/mL fortification level for set #1 and set #2, respectively, with precision values improving to 3 and 13% at the 5.100 ng/mL fortification level for set #1 and set #2, respectively.
The blood validation results for 13 C BPA surrogate show improved accuracy and precision when compared with the 12 C BPA results. The 13 C BPA accuracy ranged from of 82 to 107% across all fortification levels and the precision (RSD) ranged from 4 to 16% across all fortification levels except the 1.020 ng/mL fortification level which was 28%.
The validation results from selected urine and blood samples ( primarily at the two lowest fortification levels) were excluded based on the observed quantitation to confirmation MRM transition ratio not meeting the criteria of being +20% of the MRM transition ratio observed for the associated standards analyzed with the respective sample set (see footnotes in Table I and II).
Discussion
The goal of this study was to develop a method that allowed for interpretation of relevant (real-world) biomonitoring data in range of the targeted MQL of 0.2 and 0.5 ng/mL in blood and urine, respectively. Method performance goals were set to achieve accuracy levels between 80 and 120% and precision values (RSDs) + 20% which are consistent with recommended bioanalytical practices (15) . In addition, a third criterion was set for the sample results to be acceptable, the primary (quantitation) MRM to secondary (confirmation) MRM transition ratio observed for the samples had to be within +20% of the transition ratio observed for the standards. These stringent acceptance criteria were challenging to meet at the low targeted MQLs but were applied to define the capabilities of the method at the relevant BPA concentrations expected in real-world biomonitoring samples.
Given the broad use of 12 C BPA, many sources of trace background 12 C BPA contamination of human specimens and other materials are possible. This potential for trace background contamination from environmental sources is not unique to BPA as it has been observed when analyzing other high-volume and high use chemicals (16, 8) . In our earlier free BPA method publication (1), we identified several sources of potential BPA contamination and factors that influence accurate BPA determination were discussed in detail. In review, the sources of BPA contamination identified were sample collection devices and techniques, solvents and reagents, and laboratory supplies and techniques. In addition, we discussed the importance of using state-of-the art HPLC-MS-MS instrumentation.
An additional source of BPA contamination was observed during the conduct of this study. One set of samples showed higher than expected levels of BPA in a number of the validation samples. This elevated level was also observed in some of the reagent blanks and other controls within this respective sample set, suggesting a piece of laboratory equipment was the source of contamination. The contamination was traced, based on the reagent blank and control data, to a nitrogen blowdown apparatus used to concentrate the SPE eluate. This contamination had not been observed in previous sample sets. However, given this was a shared piece of equipment that had been used to prepare unrelated samples by another technician prior to the BPA sample set in question, it was identified as the most likely source of the contamination. This incident led to a modification in the sample preparation protocol to include an equipment cleaning procedure and the preparation and analysis of a set of reagent blanks prior to any future sample preparation for trace-level BPA determination.
This total BPA method study accounted for all of the above mentioned factors and in addition, identified a factor unique to total BPA determination (enzyme hydrolysis) that can also affect the accuracy and precision of the data generated. The use of enzyme hydrolysis to obtain total BPA has been presented in previous papers (17) with good success. However, the published techniques report hydrolysis efficiency based on test conjugate(s) and not the actual conjugate of interest (BPA-G in this case). In addition, the concentration (1 mg/mL) at which the enzyme hydrolysis confirmation was conducted previously was much higher than the targeted MQL ( 0.2 ng/mL blood, 0.5 ng/mL urine) set for this method. Therefore, several experiments were conducted during this study to evaluate different enzyme hydrolysis reagents and techniques using 12 C BPAG and 13 C BPA-G at relevant (low-level) concentrations in actual human urine and blood matrices. These experiments showed that enzyme hydrolysis efficiency (when conducting trace-level quantitation) can be compromised by several factors such as the enzyme buffer mixture, the duration of hydrolysis, the temperature and how well it is controlled and the method of sample agitation during hydrolysis. These experiments also illustrated the importance of enzyme hydrolysis efficiency confirmation using the target conjugate (BPA-G) at the target concentration and in the matrix of interest to ensure accurate determination of total BPA at low levels (low ng/mL). In addition, these experiments also showed that the enzyme viability is affected when the organic level exceeds 0.5% of the sample volume, particularity at lower concentrations (see Text Tables A and B) .
The use of a surrogate analyte ( 13 C BPA urine and 13 C BPA-G blood) showed improved accuracy and precision data when compared with 12 C BPA data at most fortification levels with marked improvement at the lower fortifications levels. This is most likely due to very low levels of 12 C BPA contamination contributions by some or all sources exogenous to the specimen but are below the limit of detection (,0.010 ng/mL) in any individual source. However, when this trace 12 C BPA is accumulated from these multiple exogenous sources it might exceed the limit of detection and hence affect the 12 C BPA results. In addition, the added enzyme hydrolysis step most likely increases the contribution to background levels of BPA. This The total 12 C BPA validation data showed acceptable accuracy and precision in human urine across all fortification levels of set #1. However, the accuracy results for set #2 exceeded the 120% criteria at the 0.510 and 2.040 ng/mL fortification levels with accuracy values of 137% and 123%, respectively.
The total 12 C BPA validation data showed more variability over the fortification range with acceptable accuracy and precision in human blood at the 0.510, 1.020 and 5.10 ng/mL fortification levels for set #1 and at 0.204, 2.550 and 5.10 ng/mL fortification levels for set #2.
These total BPA validation data in urine and blood illustrate the challenges of trace-level total BPA determination and the importance of appropriate blanks, controls, fortified controls, surrogate and sample replicates with each analysis set. This analysis strategy ensures that results from each sample set will have the critical data needed to evaluate the accuracy and precision with a high level of confidence. As a secondary benefit, this analysis strategy provides data to aid in troubleshooting method problems from sample collection to analysis.
Conclusion
In summary, this total BPA method study has a similar conclusion as the free BPA method study and again illustrates that accurate trace-level quantitation of free and/or total 12 C BPA (,1 ng/mL) in human blood and urine is very challenging. In an effort to consolidate the findings from these two studies, the authors present the following recommendations. Methods used to determine free and total 12 C BPA must strive to eliminate and continually monitor for background contamination from all sources (collection to analysis) with the appropriate blanks, controls and fortified controls. The method must demonstrate and monitor method performance using matrix spikes fortified with 12 C BPA-G at the MQL. In addition, the use of a surrogate analyte, in this case 13 C BPA-G is also strongly recommended, provides valuable information on method performance and aids in method troubleshooting as it is not affected by exogenous 12 C BPA. The total BPA method should verify enzyme hydrolysis efficiency at relevant concentrations with the target conjugates and in the study matrix. The method should analyze replicate samples or replicate matrix spikes to evaluate reproducibility. The method should employ state-of-the-art HPLC -MS-MS instrumentation to ensure the desired sensitivity and selectivity can be routinely achieved. Recently published methods have employed on-line SPE techniques with good success (18) . The advantages of online SPE over the more conventional SPE techniques used for this study are a lessened chance for contamination and potential to improve sensitivity and reproducibility. However, the additional pumping and valve switching capability required may not be readily available to all laboratories. The ultimate reason the online SPE technique was not employed for this total BPA study was to have this method be consistent with the previously published free BPA method (1). Finally, if only free 12 C BPA (unconjugated 12 C BPA) is being reported, the method must demonstrate that only free 12 C BPA is being measured by demonstrating the major metabolite of 12 C BPA ( 12 C BPA-G) is stable (no hydrolysis to free 12 C BPA) when subjected to all the method elements from sample collection to analysis.
